SCHEDULE: Vanguard Discloses 5.57% Stake in Coeptis Therapeutics

Vanguard Capital Management and its affiliates have reported beneficial ownership of 5.57% of Coeptis Therapeutics Holdings Inc. common stock as of March 31, 2026.

Summary

• Vanguard Capital Management, along with its affiliates Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC, and Vanguard Investments Australia Ltd., has disclosed a beneficial ownership stake of 346,975 shares in Coeptis Therapeutics Holdings Inc.
• This holding represents 5.57% of the company's outstanding common stock as of the filing date, March 31, 2026.
• The filing also notes that Vanguard Total Stock Market Index Fund Investor Shares holds 254,749 shares, representing 4.09% of the class.
• Vanguard Capital Management exercises sole dispositive power over 346,975 shares and sole voting power over 26,244 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While Vanguard's investment is a positive indicator, the filing itself is purely informational regarding ownership and does not provide performance data or strategic insights about Coeptis Therapeutics.

Positives

• Significant institutional ownership by a major asset manager like Vanguard can be seen as a positive signal of confidence in the company's long-term prospects.
• The disclosure indicates that Vanguard funds, which are widely held by individual investors, are invested in Coeptis Therapeutics.

Negatives

• The filing does not contain any negative financial results or operational challenges.
• No specific negative commentary is present in the document.

Risks

• The filing does not explicitly mention any current issues or potential future challenges for Coeptis Therapeutics.
• As a Schedule 13G filing, it primarily reports ownership and does not delve into company-specific operational risks.

Future Outlook

The filing does not contain any forward-looking statements or guidance from Coeptis Therapeutics. It solely reports on Vanguard's ownership stake.

Management Comments

• "In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates: Vanguard Asset Management Limited, Vanguard Fiduciary Trust Company, Vanguard Global Advisers, LLC and Vanguard Investments Australia Ltd."
• "This Schedule 13G includes securities held by Vanguard funds, or sleeves thereof, over which Vanguard Capital Management LLC exercises dispositive power, in addition to securities held by clients over which the affiliates or business divisions of such affiliates indicated above exercise dispositive and/or voting power."
• "This Schedule 13G does not include securities, if any, beneficially owned by other subsidiaries or affiliates of Vanguard Capital Management LLC, or business divisions of such subsidiaries, whose ownership of securities is disaggregated from that of the reporting business unit in accordance with such release."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that the acquisition of a significant stake by a large institutional investor like Vanguard in a company like Coeptis Therapeutics, which is likely in the biotechnology or pharmaceutical sector given its name, often signals a belief in the company's growth potential or its role within a broader industry trend such as drug development or healthcare innovation.

Stakeholder Impact

• Shareholders: The presence of a large institutional investor like Vanguard may increase investor confidence and potentially influence share price due to increased demand or perceived stability.
• Employees: Continued investment by major funds can indirectly support job security and company growth initiatives.
• Creditors: A stable or growing investor base can positively impact the company's creditworthiness.
• Suppliers: Increased company stability due to institutional investment can lead to more predictable business relationships.

Next Steps

• No specific next steps for Coeptis Therapeutics are mentioned in this filing.
• Vanguard will continue to hold or manage its investment in Coeptis Therapeutics according to its investment strategy.

Key Dates

Keywords

Coeptis Therapeutics Holdings Inc, Vanguard Capital Management, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing, Vanguard Total Stock Market Index Fund